S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
OTCMKTS:ATMS

Artemis Therapeutics News Headlines

$2.99
-0.91 (-23.33%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.20
$3.89
50-Day Range
$0.75
$3.90
52-Week Range
$0.55
$7.02
Volume
20,277 shs
Average Volume
4,201 shs
Market Capitalization
$15.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.96
Get Artemis Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATMS and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Artemis Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ATMS
News Sentiment

0.00

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ATMS Articles
This Week

0

0

ATMS Articles
Average Week



Artemis Therapeutics (OTCMKTS:ATMS) News Headlines Today

SourceHeadline
msn.com logoWashington plays key role In NASA's Artemis missions
msn.com - May 6 at 11:54 PM
in.finance.yahoo.com logoEureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myeloma
in.finance.yahoo.com - July 8 at 7:57 PM
in.finance.yahoo.com logoLendingPoint Recognized by Atlanta Business Chronicle’s Pacesetter Award for Fourth Consecutive Year
in.finance.yahoo.com - April 30 at 4:43 PM
ca.finance.yahoo.com logoCaution: Most Stocks Fail! Do This to Build a Winning Stock Portfolio
ca.finance.yahoo.com - April 30 at 4:43 PM
au.finance.yahoo.com logoEssex Communities Announces New Leadership Structure to Accommodate Rapid Growth
au.finance.yahoo.com - April 29 at 1:09 PM
au.finance.yahoo.com logo‘The Falcon and Winter Soldier’ fails to pay off on its initial promise
au.finance.yahoo.com - April 29 at 1:09 PM
seekingalpha.com logoLineage: OPC1, VAC2, And OpRegen Are Making Progress With Several 2020 Catalysts, 48% Upside
seekingalpha.com - November 18 at 3:07 PM
finance.yahoo.com logoArtemis Therapeutics Announces Additional Patent Issuance For Artemisone For The Treatment Of Viral Infections
finance.yahoo.com - January 21 at 3:44 PM
finance.yahoo.com logoNew Data Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication
finance.yahoo.com - January 21 at 3:44 PM
finance.yahoo.com logoData Presented At The 31st International Conference For Antiviral Research Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication
finance.yahoo.com - January 21 at 3:44 PM
finance.yahoo.com logoArtemis Therapeutics Announces Two Recent Publications Highlighting Artemisone's Activity Against Human Cytomegalovirus And Malaria
finance.yahoo.com - January 21 at 3:44 PM
Get Artemis Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATMS and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.